SEHK:3933Pharmaceuticals
Assessing United Laboratories International Holdings (SEHK:3933) Valuation After Positive UBT251 Phase 2 Trial Results
Phase 2 data on UBT251 puts United Laboratories International Holdings in focus
United Laboratories International Holdings (SEHK:3933) drew investor attention after releasing phase 2 data for UBT251 in China, showing HbA1c and body weight reductions against placebo and semaglutide in type 2 diabetes patients.
The topline readout matters because it moves UBT251 closer to late stage development, supports the start of phase 3 trials in China, and ties directly into the company’s broader diabetes...